SeekingAlphaAugust 14, 2026 at 10:22 AM NY21 days ago
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming
Nektar Therapeutics earns a Strong Buy on REZPEG Phase 3 AD/AA upside, $1.02B cash runway to 2028, and big market opportunity. Click for this NKTR update.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha
Companies in This Story
Related Stories
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
Yahoo3 hours ago
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill1 hour ago
Discover which S&P500 stocks are making waves on Friday.
ChartMill2 hours ago
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo3 hours ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo3 hours ago